Key Factors to Evaluate Before Investing in Sanofi ADS (SNY)

By Harris Dyer • Thursday, July 03 15:15 • Permanent Link

More and more people are talking about Sanofi ADS over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $48.3? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Sanofi ADS has moved -0.7% over the last year, and the S&P 500 logged a change of 11.9%
SNY has an average analyst rating of buy and is -24.38% away from its mean target price of $63.87 per share
Its trailing earnings per share (EPS) is $2.94
Sanofi ADS has a trailing 12 month Price to Earnings (P/E) ratio of 16.4 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $4.94 and its forward P/E ratio is 9.8
The company has a Price to Book (P/B) ratio of 0.78 in contrast to the S&P 500's average ratio of 4.74
Sanofi ADS is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
SNY has reported YOY quarterly earnings growth of 67.2% and gross profit margins of 0.7%
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.